Navigation Links
Degradation of viral DNA in the cell nucleus is opening up new treatment
Date:2/21/2014

Viruses such as HBV can persist by depositing their genetic information (DNA) in the cell nucleus, where the DNA is normally not degraded. This prevents antiviral drugs from eliminating these viruses. But the newly discovered mechanism could make this possible without damaging the infected cell in the liver. In the current issue of the prestigious journal 'Science', the scientists report that now new therapeutic possibilities are consequently opening up.

Although preventive vaccination is possible, the World Health Organization (WHO) reports that more than 240 million people around the world are currently suffering from a chronic hepatitis B infection. They face a high risk of developing liver cirrhosis or even liver cancer. In Germany alone, more than half a million people are affected. Although available antiviral medicines can control the hepatitis B virus, they cannot completely eliminate it. As a result, the HBV in the patient's liver is reactivated as soon as the treatment is discontinued.

This is due to virus DNA (cccDNA: covalently closed circular DNA) "hidden" in the cell nucleus. This virus DNA stores multiple copies of the virus in the nucleus of infected liver cells (hepatocytes) and in this way protects itself from destructive influences. The cccDNA serves as a template for the virus' own proteins and new viral genomes. An international team of scientists headed by Prof. Ulrike Protzer and Prof. Mathias Heikenwlder, Institute of Virology at the Helmholtz Zentrum Mnchen and the Technische Universitt Mnchen, has now found a way to selectively attack and eliminate the viral genetic information in the cell nucleus of the liver cells without damaging the host cell in the process.

"The degradation of viral DNA in the cell nucleus that we describe represents an important mechanism in the defence against the virus", Protzer reports. "Moreover, for the first time, the results offer the possibility to develop a treatment that can heal hepatitis B."

The scientists have discovered that in addition to interferons (the immune system's defence agents), activation of the lymphotoxin β receptor in the host cell promotes certain proteins and supports their function in such a way that they chemically modulate and degrade viral cccDNA. This keeps the virus from reactivating, and also prevents the disease from breaking out again, even after the treatment has ended.

On the other hand, the proteins do not influence the genetic information of the host cell itself, which here is the liver cell. "With the activation of the lymphotoxin β receptor, also combined with substances that are already available, we have a very promising new therapy concept available", Heikenwlder explains.


'/>"/>

Contact: Ulrike Protzer
protzer@helmholtz-muenchen.de
49-894-140-6886
Helmholtz Zentrum Mnchen - German Research Center for Environmental Health
Source:Eurekalert

Related biology news :

1. Streams show signs of degradation at earliest stages of urban development
2. Scientists discover new way protein degradation is regulated
3. Pollination, land degradation: Top priorities for assessment by new UN intergovernmental body
4. Loss of biodiversity limits toxin degradation
5. Discovery offers insight into treating viral stomach flu
6. Women & Infants participating in study of treatment of common viral infection in pregnancy
7. Vitamin D supplements may protect against viral infections during the winter
8. The physics of going viral
9. New study shows promise in using RNA nanotechnology to treat cancers and viral infections
10. Viral alliances overcoming plant defenses
11. Protein production: Going viral
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/8/2019)... ... May 08, 2019 , ... Great Point Partners ... provider of unified eClinical solutions and services that are used to enhance the ... is a leading e-clinical technology company that focuses on Electronic Data Capture (“EDC”), ...
(Date:5/2/2019)... , ... April 30, 2019 , ... ... in Cambridge, MA, announces today that Holotype HLA and other Omixon products will ... European Federation for Immunogenetics (EFI) in Lisbon, Portugal. Among the major scientific ...
(Date:4/25/2019)... ... April 23, 2019 , ... Leak Detection Associates, the world’s ... Medical Device and Food Packaging Industries’ is pleased to announce the completion of ... The new facility was custom designed to meet enhanced manufacturing capabilities that will ...
Breaking Biology News(10 mins):
(Date:4/16/2019)... ... April 16, 2019 , ... On April 24th, ... the U.S. Army Center for Environmental Health Research (USACEHR), with an award for ... Blue Sources, a veteran-owned company located at the Frederick Innovative Technology Center, Inc. ...
(Date:4/12/2019)... ... April 12, 2019 , ... ... in neurotechnology and will educate about innovative tools and devices being used to ... listings for more information. , This segment of Advancements will focus on Sound ...
(Date:4/9/2019)... (PRWEB) , ... April 09, 2019 , ... ... firm focused on increasing the capacity of life sciences organizations to accelerate innovation ... Cloud Assurance platform in the past 12 months. , USDM’s Cloud ...
(Date:4/8/2019)... and BOSTON (PRWEB) , ... April 08, 2019 ... ... cloud-based enterprise-class unified communications and collaboration solutions, announced today the launch of their ... to an unprecedented range of business and contact-orientated applications while using CT Cloud ...
Breaking Biology Technology: